Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01105247.).